Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology

Survivorship: Monitoring and Life After Maintenance

At a Glance

After completing Acute Lymphoblastic Leukemia (ALL) maintenance therapy, patients enter a surveillance phase to monitor for relapse and late effects. Care involves regular blood work, minimal residual disease (MRD) testing, and following a personalized Survivorship Care Plan.

Completing the long maintenance phase of Acute Lymphoblastic Leukemia (ALL) treatment is a massive milestone. However, the transition from “active patient” to “survivor” can bring its own set of challenges, ranging from physical late effects to the emotional weight of “scan anxiety” [1][2]. Survivorship is not just about the absence of disease; it is about managing the long-term impact of the therapy that saved your life [3][4].

Monitoring Your Recovery

Once you finish maintenance treatment, your medical team will move you into a surveillance phase. The goal is to monitor for any signs of the cancer returning and to catch any treatment-related side effects early [5][6].

  • Frequency of Checks: In the first year after treatment, you will likely have blood work (Complete Blood Counts or CBCs) every 1–2 months. Over time, these visits will become less frequent—moving to every 3, 6, and eventually 12 months [7][8].
  • Minimal Residual Disease (MRD): Instead of frequent bone marrow biopsies, doctors now rely heavily on highly sensitive MRD testing to ensure no “hidden” leukemia cells are reappearing [9][10].
  • Long-Term Clinics: Many patients eventually transition to a Long-Term Follow-Up (LTFU) clinic, which uses the Children’s Oncology Group (COG) guidelines to provide a personalized roadmap for your lifelong health [11][12].

Potential Late Effects

Because ALL treatment is intensive, it can sometimes cause “late effects”—health issues that show up months or even years after treatment ends [3][13].

Area of Health Potential Issue What to Know
Brain & Focus Neurocognitive Effects Intrathecal chemo (spinal taps) can sometimes lead to “brain fog,” or trouble with attention and memory [14][15].
Bone Health Osteonecrosis High doses of steroids (like dexamethasone) can sometimes damage bone tissue, particularly in the hips or knees [16][17].
Heart Health Cardiotoxicity Certain chemotherapy drugs (anthracyclines) can weaken the heart muscle over time. Regular echocardiograms may be needed [12][18].
Future Risks Secondary Cancers While rare, survivors have a slightly higher risk of developing a different type of cancer later in life due to prior chemo or radiation [19][20].

Navigating the Emotional Toll

It is common to feel a sense of “lost safety” when you are no longer receiving treatment every day. Scan anxiety—the fear that every blood test or minor ache means the cancer is back—is a very real experience for many survivors [2].

  • Acknowledge the Fear: Feeling anxious before appointments is a normal response to a traumatic experience [21].
  • Seek Support: Specialized therapies, such as Metacognitive Therapy (MCT), have been shown to help survivors manage the fear of recurrence and improve their overall quality of life [21][2].
  • Be Patient with Yourself: Your body and mind have been through a “marathon.” It takes time to find your “new normal” in the years following treatment [1].

Your Survivorship Care Plan (SCP) is your most important document during this time. It should list every drug you received, the total doses, and exactly which screenings you need for the rest of your life [3][22].

Common questions in this guide

What kind of monitoring will I need after ALL maintenance therapy?
In your first year after treatment, you will typically have blood work every one to two months. Your doctor will also use highly sensitive minimal residual disease (MRD) testing to ensure no leukemia cells are returning.
What is a Survivorship Care Plan for leukemia?
A Survivorship Care Plan is a personalized document that lists every medication and the total doses you received during treatment. It provides a lifelong roadmap for exactly which health screenings you will need in the future.
Can leukemia treatment cause long-term side effects?
Yes, intensive chemotherapy and steroids can cause late effects that appear months or years after treatment ends. These can include issues with bone health, heart muscle weakness, brain fog, or a slightly higher risk of secondary cancers.
How often should my heart be checked after ALL treatment?
Because certain chemotherapy drugs like anthracyclines can weaken the heart over time, regular echocardiograms may be needed. Your oncologist will determine your exact screening schedule based on the total doses of medication you received.
How can I cope with the fear of my cancer returning?
Experiencing scan anxiety and fearing relapse is a normal response to finishing cancer treatment. Seeking support through specialized counseling, such as Metacognitive Therapy, can help you manage these fears and improve your quality of life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you provide me with a 'Survivorship Care Plan' that lists all the medications and cumulative doses I received?
  2. 2.What is the schedule for my blood work (CBCs) and MRD monitoring for the first two years after maintenance?
  3. 3.Based on my total steroid dose, should I have an MRI or screening for bone health (osteonecrosis)?
  4. 4.When should I have my first post-treatment echocardiogram to check my heart health?
  5. 5.What signs of a secondary cancer should I be looking for in the coming years?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Life is an ongoing existential battle - experiences from adult survivors after allogeneic hematopoietic stem cell transplantation during childhood acute lymphoblastic leukemia.

    Olsson M, Aili K, Jarfelt M, et al.

    European journal of oncology nursing : the official journal of European Oncology Nursing Society 2025; (77()):102929 doi:10.1016/j.ejon.2025.102929.

    PMID: 40701078
  2. 2

    Brief Metacognitive Therapy for Emotional Distress in Adult Cancer Survivors.

    Fisher PL, Byrne A, Fairburn L, et al.

    Frontiers in psychology 2019; (10()):162 doi:10.3389/fpsyg.2019.00162.

    PMID: 30766505
  3. 3

    The Impact of Persistent Leukoencephalopathy on Brain White Matter Microstructure in Long-Term Survivors of Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.

    Sabin ND, Cheung YT, Reddick WE, et al.

    AJNR. American journal of neuroradiology 2018; (39(10)):1919-1925 doi:10.3174/ajnr.A5791.

    PMID: 30213807
  4. 4

    Risk Stratification and Cancer Follow-Up: Towards More Personalized Post-Treatment Care in Canada.

    Urquhart R, Cordoba W, Bender J, et al.

    Current oncology (Toronto, Ont.) 2022; (29(5)):3215-3223 doi:10.3390/curroncol29050261.

    PMID: 35621651
  5. 5

    A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.

    Keeney M, Wood BL, Hedley BD, et al.

    Cytometry. Part B, Clinical cytometry 2018; (94(2)):239-249 doi:10.1002/cyto.b.21528.

    PMID: 28475275
  6. 6

    Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia.

    Shah G, Mikhail FM, Carroll AJ, et al.

    Case reports in hematology 2019; (2019()):3536517 doi:10.1155/2019/3536517.

    PMID: 30805228
  7. 7

    Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.

    Schumich A, Maurer-Granofszky M, Attarbaschi A, et al.

    Pediatric blood & cancer 2019; (66(5)):e27590 doi:10.1002/pbc.27590.

    PMID: 30561169
  8. 8

    IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.

    Alsadeq A, Lenk L, Vadakumchery A, et al.

    Blood 2018; (132(15)):1614-1617 doi:10.1182/blood-2018-04-844209.

    PMID: 30154115
  9. 9

    A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia.

    Bassan R, Brüggemann M, Radcliffe HS, et al.

    Haematologica 2019; (104(10)):2028-2039 doi:10.3324/haematol.2018.201053.

    PMID: 30890593
  10. 10

    Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.

    Hein K, Short N, Jabbour E, Yilmaz M

    Blood and lymphatic cancer : targets and therapy 2022; (12()):7-16 doi:10.2147/BLCTT.S270134.

    PMID: 35340663
  11. 11

    Long-term Follow-up Care for Childhood, Adolescent, and Young Adult Cancer Survivors.

    Hudson MM, Bhatia S, Casillas J, et al.

    Pediatrics 2021; (148(3)) doi:10.1542/peds.2021-053127.

    PMID: 34462344
  12. 12

    The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review.

    DeVine A, Landier W, Hudson MM, et al.

    JAMA oncology 2025; (11(5)):544-553 doi:10.1001/jamaoncol.2024.6812.

    PMID: 39976936
  13. 13

    Mechanisms by Which Obesity Impacts Survival from Acute Lymphoblastic Leukemia.

    Orgel E, Sea JL, Mittelman SD

    Journal of the National Cancer Institute. Monographs 2019; (2019(54)):152-156 doi:10.1093/jncimonographs/lgz020.

    PMID: 31532535
  14. 14

    Brainstem auditory pathway of children with acute lymphoid leukemia on chemotherapy with methotrexate.

    Leite RA, Vosgrau JS, Cortez Neto L, et al.

    Arquivos de neuro-psiquiatria 2020; (78(2)):63-69 doi:10.1590/0004-282X20190139.

    PMID: 32022120
  15. 15

    Characterizing Parental Concerns About Lasting Impacts of Treatment in Children With B-Acute Lymphoblastic Leukemia.

    Parker KN, Alexander SW, Jacola LM, et al.

    Pediatric blood & cancer 2026; (73(4)):e70156 doi:10.1002/1545-5017.70156.

    PMID: 41574635
  16. 16

    Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.

    Ramsey LB, Janke LJ, Payton MA, et al.

    PloS one 2015; (10(8)):e0135134 doi:10.1371/journal.pone.0135134.

    PMID: 26252865
  17. 17

    Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis.

    Finch ER, Janke LJ, Smith CA, et al.

    Pediatric blood & cancer 2019; (66(6)):e27669 doi:10.1002/pbc.27669.

    PMID: 30758124
  18. 18

    A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen.

    Watson C, Gadikota H, Barlev A, Beckerman R

    Journal of drug assessment 2022; (11(1)):1-11 doi:10.1080/21556660.2022.2073101.

    PMID: 35693477
  19. 19

    A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine.

    Hu M, Li W, Li P, et al.

    Frontiers in oncology 2024; (14()):1329279 doi:10.3389/fonc.2024.1329279.

    PMID: 38737911
  20. 20

    First case of B ALL with KMT2A-MAML2 rearrangement: a case report.

    Menu E, Beaufils N, Usseglio F, et al.

    BMC cancer 2017; (17(1)):363 doi:10.1186/s12885-017-3368-4.

    PMID: 28535805
  21. 21

    Metacognitive Therapy for Emotional Distress in Adult Cancer Survivors: A Case Series.

    Fisher PL, Byrne A, Salmon P

    Cognitive therapy and research 2017; (41(6)):891-901 doi:10.1007/s10608-017-9862-9.

    PMID: 29104332
  22. 22

    Altered brain function in new onset childhood acute lymphoblastic leukemia before chemotherapy: A resting-state fMRI study.

    Hu Z, Zou D, Mai H, et al.

    Brain & development 2017; (39(9)):743-750 doi:10.1016/j.braindev.2017.04.014.

    PMID: 28545980

This page provides educational information about Acute Lymphoblastic Leukemia survivorship and late effects. Always discuss your specific monitoring needs and Survivorship Care Plan with your oncology team.

Get notified when new evidence is published on Acute lymphoblastic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.